These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 22003129)

  • 1. Subtype and pathway specific responses to anticancer compounds in breast cancer.
    Heiser LM; Sadanandam A; Kuo WL; Benz SC; Goldstein TC; Ng S; Gibb WJ; Wang NJ; Ziyad S; Tong F; Bayani N; Hu Z; Billig JI; Dueregger A; Lewis S; Jakkula L; Korkola JE; Durinck S; Pepin F; Guan Y; Purdom E; Neuvial P; Bengtsson H; Wood KW; Smith PG; Vassilev LT; Hennessy BT; Greshock J; Bachman KE; Hardwicke MA; Park JW; Marton LJ; Wolf DM; Collisson EA; Neve RM; Mills GB; Speed TP; Feiler HS; Wooster RF; Haussler D; Stuart JM; Gray JW; Spellman PT
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2724-9. PubMed ID: 22003129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking signaling pathways to transcriptional programs in breast cancer.
    Osmanbeyoglu HU; Pelossof R; Bromberg JF; Leslie CS
    Genome Res; 2014 Nov; 24(11):1869-80. PubMed ID: 25183703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines.
    Shen K; Rice SD; Gingrich DA; Wang D; Mi Z; Tian C; Ding Z; Brower SL; Ervin PR; Gabrin MJ; Tseng G; Song N
    PLoS One; 2012; 7(7):e40900. PubMed ID: 22815861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
    Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
    Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling precision treatment of breast cancer.
    Daemen A; Griffith OL; Heiser LM; Wang NJ; Enache OM; Sanborn Z; Pepin F; Durinck S; Korkola JE; Griffith M; Hur JS; Huh N; Chung J; Cope L; Fackler MJ; Umbricht C; Sukumar S; Seth P; Sukhatme VP; Jakkula LR; Lu Y; Mills GB; Cho RJ; Collisson EA; van't Veer LJ; Spellman PT; Gray JW
    Genome Biol; 2013; 14(10):R110. PubMed ID: 24176112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
    Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
    Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    Lehmann BD; Bauer JA; Chen X; Sanders ME; Chakravarthy AB; Shyr Y; Pietenpol JA
    J Clin Invest; 2011 Jul; 121(7):2750-67. PubMed ID: 21633166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    Huang S; Hu P; Lakowski TM
    BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients.
    Xu Y; Lin S; Zhao H; Wang J; Zhang C; Dong Q; Hu C; Desi S; Wang L; Xu Y
    Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31466383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
    Eroles P; Bosch A; Pérez-Fidalgo JA; Lluch A
    Cancer Treat Rev; 2012 Oct; 38(6):698-707. PubMed ID: 22178455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
    Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
    Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors.
    Creighton CJ
    PLoS One; 2013; 8(12):e71158. PubMed ID: 24386073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
    Ghayad SE; Cohen PA
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
    Robles AJ; Du L; Cichewicz RH; Mooberry SL
    J Nat Prod; 2016 Jul; 79(7):1822-7. PubMed ID: 27310425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic effect of noscapine in breast cancer cell lines.
    Quisbert-Valenzuela EO; Calaf GM
    Int J Oncol; 2016 Jun; 48(6):2666-74. PubMed ID: 27081867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.